GILD · XBRL financial data

Gilead Sciences financial statements, every fiscal year

The same tables from 6 filings, lined up. Matched by XBRL tag: renamed lines keep their history.

How these numbers work

Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
* marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
0 means a filing states zero; a dash (—) means no filing states that number.
“year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
Shares outstanding come from each filing's cover page, as of the date printed there.
Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.

Income statement

Fiscal years (GILD's year ends in late December)

In millions of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Revenue	24,689	—	—	—	—	—
Revenue from contracts with customers	24,689	27,305	27,281	27,116	28,754	29,443
Cost of goods and services sold	4,572	6,601	5,657	6,498	6,251	6,234
Selling, general and administrative	5,151	5,246	5,673	6,090	6,091	5,774
Operating income (loss)	4,071	9,918	7,330	7,605	1,662	10,022
Interest expense	984	1,001	935	944	977	1,024
Other income (expense)	—	—	(29)	(11)	(2)	(1)
Income tax expense (benefit)	1,580	2,077	1,248	1,247	211	1,286
Net income (loss)	123	6,225	4,592	5,665	480	8,510
Earnings per share, basic USD per share	0.10	4.96	3.66	4.54	0.38	6.84
Earnings per share, diluted USD per share	0.10	4.93	3.64	4.50	0.38	6.78
Weighted average shares, basic millions of shares	1,257	1,256	1,255	1,248	1,247	1,244
Weighted average shares, diluted millions of shares	1,263	1,262	1,262	1,258	1,255	1,255

Fiscal years (GILD's year ends in late December)

In millions of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Cash and cash equivalents	5,997	5,338	5,412	6,085	9,991	7,564
Marketable securities	1,411	1,182	973	1,179	0	68
Marketable securities, non-current	502	1,309	1,245	1,163	0	2,974
Accounts receivable	4,892	4,493	4,777	4,660	4,420	4,913
Inventory	1,683	1,618	1,507	1,787	1,710	1,774
Prepaid and other current assets	2,013	2,141	1,774	2,374	3,052	4,024
Total current assets	15,996	14,772	14,443	16,085	19,173	18,342
Property and equipment, net	4,967	5,121	5,475	5,317	5,414	5,606
Right-of-use asset	646	542	505	581	515	532
Goodwill	8,108	8,332	8,314	8,314	8,314	8,314
Total assets	68,407	67,952	63,171	62,125	58,995	59,023
Accounts payable	844	705	905	550	833	715
Accrued liabilities	4,336	6,145	—	—	—	—
Current portion of long-term debt	2,757	1,516	2,273	1,798	1,815	2,807
Total current liabilities	11,397	11,610	11,237	11,280	12,004	11,813
Long-term debt	28,645	25,179	22,957	23,189	24,896	22,129
Lease liability, non-current	608	489	467	546	498	503
Retained earnings	14,381	16,324	15,687	16,304	11,497	13,730
Total stockholders' equity	18,202	21,069	21,240	22,833	19,330	22,703
Total liabilities and equity	68,407	67,952	63,171	62,125	58,995	59,023
Common shares outstanding (cover page) millions of shares	1,257	1,254	1,247	1,246	1,245	1,241

Fiscal years (GILD's year ends in late December)

In millions of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Net income (loss)	123	6,225	4,592	5,665	480	8,510
Stock-based compensation	643	635	637	766	835	894
Net cash from operating activities	8,168	11,384	9,072	8,006	10,828	10,019
Purchases of property and equipment	650	579	728	585	523	563
Net cash from investing activities	(14,615)	(3,131)	(2,466)	(2,265)	(3,449)	(4,793)
Proceeds from issuing common stock	256	169	309	232	422	408
Share repurchases	1,583	546	1,396	1,000	1,150	1,922
Dividends paid	3,449	3,605	3,709	3,809	3,918	4,003
Repayments of long-term debt	—	4,750	—	—	—	—
Net cash from financing activities	770	(8,877)	(6,469)	(5,125)	(3,433)	(7,745)
Net change in cash	(5,634)	(659)	74	673	3,906	(2,428)

SIC 2836 and related industry codes, similar size. Each row is the latest quarter reported.

How peers are chosen

SIC 2836 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
* marks a quarter worked out from the filing totals: for a 10-Q, the year-to-date total less the earlier one.
A cell reading “not reported” means the filings give no figure for that quarter alone.

Company	Cash ($M)	Revenue, quarter ($M)	Operating cash flow, quarter ($M)	Shares outstanding	Quarter
Gilead Sciences	6,437	8,300	5,035*	1.2B	Q3 FY26 10-QSep 30, 2026
Bristol Myers Squibb	9,574	13,069	4,181*	2.0B	Q3 FY26 10-QSep 30, 2026
Vertex Pharmaceuticals	4,979	3,441	643*	253.5M	Q3 FY26 10-QSep 30, 2026
Pfizer	1,824	16,583	5,375*	5.7B	Q3 FY26 10-QSep 27, 2026
Amgen	13,190	10,365	4,241*	540.9M	Q3 FY26 10-QSep 30, 2026
Zoetis	1,333	2,391	not reported	406.3M	Q3 FY26 10-QSep 30, 2026
Regeneron Pharmaceuticals	3,659	5,116	1,783*	not reported	Q3 FY26 10-QSep 30, 2026
Merck	9,550	18,085	6,558*	2.5B	Q3 FY26 10-QSep 30, 2026
Abbott Laboratories	4,052	13,013	1,737*	1.7B	Q3 FY26 10-QSep 30, 2026

Not investment advice. Not affiliated with the U.S. SEC.